Skip to content

Clinical Observation of Erdi Bazhen Decoction in Treating Cancer-Related Fatigue (CRF) due to Qi and Blood Deficiency in Prostate Cancer Patients after Androgen Deprivation Therapy from the Perspective of 'Qi and Blood Disharmony'

Clinical Observation of Erdi Bazhen Decoction in Treating Cancer-Related Fatigue (CRF) due to Qi and Blood Deficiency in Prostate Cancer Patients after Androgen Deprivation Therapy from the Perspective of 'Qi and Blood Disharmony'

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001527
Enrollment
Unknown
Registered
2026-06-20
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-Related Fatigue after Androgen Deprivation Therapy for Prostate Cancer

Interventions

Treatment group:Conventional treatment + Erdi Bazhen Decoction instant granules.
Control Group:Conventional treatment + Erdi Bazhen Decoction placebo.

Sponsors

Chengdu University of Traditional Chinese Medicine Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria for androgen deprivation therapy-induced Cancer-Related Fatigue patients: 1) Confirmed diagnosis of prostate cancer and Cancer-Related Fatigue, currently undergoing androgen deprivation therapy; 2) Meets TCM diagnostic criteria for Qi and Blood Deficiency; 3) Male aged 45-85 years; 4) Expected survival =6 months; 5) Fatigue clearly caused by prostate cancer or related factors; 6) Conscious, cognitively normal, able to complete questionnaires; 7) Willing to participate and provide signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1) Subjects meeting any of the following criteria will be excluded from the study: 2)Having severe primary diseases of the cardiovascular system, liver, kidney, lung, liver, and hematological system 3)Known allergy to any ingredient of Erdi Bazhen Decoction or the excipients used in the trial; 4)Patients with severe infection; 5)Concurrent presence of other malignant tumors; 6)In the judgment of the investigator, any condition that is inconsistent with the subject's best interest for participating in the study, or that may impede, restrict, or interfere with the protocol-specified assessments; 7)Legal disability (including blindness, deafness, muteness, intellectual disability) or mental illness.

Design outcomes

Primary

MeasureTime frame
Fatigue Improvement;

Secondary

MeasureTime frame
Quality of Life Indicator;Functional Status;TCM Syndrome Score;Objective Lab's Indicators;

Countries

China

Contacts

Public ContactZiyang Ma

Chengdu University of Traditional Chinese Medicine Affiliated Hospital

593292085@qq.com17628059726

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026